Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 5, 2005, Pages 1125-1131

  Cramer, Daniel W ^a   Titus Ernstoff, Linda ^b   McKolanis, John R ^c   Welch, William R ^a   Vitonis, Allison F ^a   Berkowitz, Ross S ^a   Finn, Olivera J ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; MUCIN 1; TALC; TUMOR ANTIGEN;

AGED; ANTIGEN RECOGNITION; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; FRACTURE; HUMAN; HUMAN TISSUE; IMMUNITY; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MASTITIS; ORAL CONTRACEPTION; OSTEOPOROSIS; OVARY; OVARY CANCER; PELVIS SURGERY; PRIORITY JOURNAL; PROGNOSIS; SMOKING;

ADULT; AGED; BOSTON; CA-15-3 ANTIGEN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 18544377499     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0035     Document Type: Article

References (46)

1. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51.
2. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994;54:2856-60.
3. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, et al. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast rumours. Eur J Cancer 1996;32:1325-31.
4. Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 1998;46:245-52.
5. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003;103:97-100.
6. Vlad AD, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004;82:249-93.
7. Agrawal B, Reddish MA, Krantz MJ, Longenecker BM. Does pregnancy immunize against breast cancer? Cancer Res 1995;55:2257-61.
8. Janerich DT. The influence of pregnancy on breast cancer risk: is it endocrinological or immunological? Med Hypotheses 1980;6:1149-55.
9. Forsman LM, Jouppila PI, Andersson LC. Sera from multiparous women contain antibodies mediating cytotoxicity against breast carcinoma cells. Scand J Immunol 1984;19:135-9.
10. Shields LB, Gercel-Taylor C, Yashar CM, et al. Induction of immune responses to ovarian tumor antigens by multiparity. J Soc Gynecol Investig 1997;4:298-304.
11. Agrawal B, Reddish MA, Longenecker BM. In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 1996;157:2089-95.
12. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol 1995;57: 607-34.
13. Fontenot JD, Mariappan SV, Catasti P, Domenech N, Finn OJ, Gupta G. Structure of a tumor associated antigen containing a tandemly repeated immunodominance epitope. J Biomol Struct Dyn 1995;3:245-60.
14. McGuckin MA, Ramm LE, Joy GJ, Devine PL, Ward BG. Circulating tumor associated mucin concentrations determined by the CASA assay in healthy women. Clin Chim Acta 1993;214:139-51.
15. Bon GG, Kenemans P, Verstraeten AA, et al. Maternal serum Ca125 and Ca 15-3 antigen levels in normal and pathological pregnancy. Fetal Diagn Ther 2001;16:166-72.
16. Croce MV, Isla-Larrain MT, Price MR, Segal-Eiras A. Detection of circulating mammary mucin (Muc1) and MUC1 immune complexes (Muc1-CIC) in healthy women. Int J Biol Markers 2001;16:112-20.
17. Hinoda Y, Nakagawa N, Nakamura H, et al. Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis. Immunol Lett 1993;35:163-8.
18. Gipson IK, Ho SB, Spurr-Michaud SJ, et al. Mucin genes expressed by human female reproductive tract epithelia. Biol Reprod 1997;56:999-1011.
19. Hankinson SE, Hunter DJ, Colditz GA. Tubal ligation, hysterectomy, and risk of ovarian cancer. JAMA 1993;270:2813-8.
20. Green A, Purdie PD, Bain C, et al. Tubal sterilization, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer 1997;71:948-51.
21. Hester LL Jr, Kellert WW III, Spicer SS, Williamson HO, Pratt-Thomas HR. Effects of the intrauterine contraceptive device on endometrial enzyme and carbohydrate histochemistry. Am J Obstet Gynecol 1970;106:1144-54.
22. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002;57:120-8.
23. Sivridis E, Giatromanolaki A, Koukourakis MI, Georgiou L, Anastasiadis P. Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance. Histopathology 2002;40:92-100.
24. Papadopoulos NG, Georganas K, Skoutellas V, Konstantellos E, Lyritis GP. Correlation of interueukin-6 serum levels with bone density in postmenopausal women. Clin Rheumatol 1997;16:162-5.
25. Strecker W, Gebhard F, Rager J, Bruckner UB, Steinbach G, Kinzl L. Early biochemical characterization of soft-tissue trauma and fracture trauma. J Trauma Injury Infect Crit Care 1999;47:358-64.
26. Gaemers IC, Vox HL, Volders HH, van der Valk SW, Hilkens J. A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem 2001;276:6191-9.
27. Brugger W, Buhring HJ, Grunebach F, et al. Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol 1999;17:1535-44.
28. Newcomb PA, Trentham-Dietz A, Egan KM, et al. Fracture history and risk of breast and endometrial cancer. Am J Epidemiol 2001;153:1071-8.
29. Terry PD, Miller AB, Rohan TE. A prospective cohort study of cigarette smoking and the risk of endometrial cancer. Br J Cancer 2002;86:1430-5.
30. Brinton LA, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD. Cigarette smoking and the risk of endometrial cancer. Am J Epidemiol 1993; 137:281-91.
31. Pan SY, Ugnat AM, Mao Y, Wen SW, Johnson KC. Association of cigarette smoking and the risk of ovarian cancer. Int J Cancer 2004;111:124-30.
32. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Cigarette smoking and increased risk of mucinous epithelial ovarian cancer. Am J Epidemiol 2004;159:33-9.
33. McIntyre R, Bigler L, Dellinger T, Pfeifer M, Mannery T, Stredkfus C. Oral contraceptive usage and the expression of CA 15-3 and c-erB-2 in the saliva of healthy women. Oral Surg Med Pathol Radiol Endod 1999;88: 687-90.
34. Hild-Petito S, Fazleabas AT, Julian J, Carson DD. Mucin (Muc-1) expression is differentially regulated in uterine luminal and glandular epithelia of the baboon (Papio anubis). Biol Reprod 1993;54:939-47.
35. Hewetson A, Chilton BS. Molecular cloning and hormone-dependent expression of rabbit Muc1 and the cervix and uterus. Biol Reprod 1997; 57:468-77.
36. Jerome KR, Kir AD, Pecher G, Ferguson WW, Finn OJ. A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. Cancer Immunol Immunother 1997;43:355-60.
37. D'Agostino P, Camemi AR, Arcoleo F, et al. Matrix metalloproteinases production in malignant pleural effusions after talc pleuodesis. Clin Exp Immunol 2003;34:138-42.
38. Gross AJ, Berg PH. A meta-analytical approach examining the potential relationship between talc exposure and ovarian cancer. J Expo Anal Environ Epidemiol 1995;5:181-95.
39. Cramer DW, Liberman RF, Titus-Ernstoff L, et al. Genital talc exposure and risk of ovarian cancer. Int J Cancer 1999;81:351-6.
40. Huncharek M, Gerschwind JF, Kupelnick B. Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies. Anticancer Res 2003; 23:1955-60.
41. Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia? Lancet 1971; 2:163.
42. Cramer DE, Welch WR. Determinants of ovarian cancer risk. II. Inference regarding pathogenesis. Natl Cancer Inst 1983;1:717-21.
43. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999;91:1459-67.
44. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998; 90:1774-86.
45. West RD. Epidemiologic study of malignancies of the ovaries. Cancer 1966; 19:1001.
46. Newhouse ML, Pearson RM, Fullerton JM, Boesen EA, Shannon HS. A case control study of carcinoma of the ovary. Br J Prev Soc Med 1977;31:148-53.